Jim Cramer Says to Buy UnitedHealth Group Stock. Is He Right?

UnitedHealth stock has surged 57% since March 30 to about $408 per share, helped by CMS proposing a 2.48% increase in Medicare Advantage rates for 2027. The article argues the stock remains attractive at 21x forward earnings, with 77% of analysts rating it a buy and a median price target of $420. It also highlights a recent earnings beat, raised 2026 guidance, and the stock's defensive dividend profile.

Analysis

The immediate winner here is not just UNH, but the entire managed-care complex’s implied earnings power. A higher CMS rate reset reduces the probability of a near-term margin reset, which matters because the market had been pricing the sector as though medical cost trends would stay structurally hostile; that multiple compression is now partially unwinding. The second-order effect is that capital is likely to rotate from defensive skepticism back into quality compounders with visible underwriting leverage, while the weakest operators remain trapped in a credibility discount.

The interesting nuance is that this is still an earnings-quality story, not just a valuation story. If management can convert a friendlier reimbursement backdrop into cleaner 2026 guidance and lower estimate dispersion, the stock can keep rerating even without heroic revenue growth. That said, the move has already de-risked the name materially, so the next leg likely depends on whether utilization and pricing discipline stay benign over the next 2-3 reporting cycles rather than on further policy headlines.

Consensus may be underappreciating how asymmetric the setup is for relative performance versus peers. UNH is the cleanest expression of policy relief plus operational repair, while HUM remains more levered to any disappointment in Medicare Advantage economics and therefore offers a cleaner way to express skepticism about how broad the benefit really is. The market is also likely overvaluing the durability of the move if it assumes one favorable CMS print eliminates longer-term medical cost pressure; if utilization inflects in the back half of the year, the stock can easily stall even with decent fundamentals.

The main risk is a classic ‘good-news squeeze’ that fades once the policy catalyst is fully discounted. Over a 1-3 month horizon, the trade is vulnerable to any sign that cost trends or guidance revisions are less clean than expected; over 6-12 months, the key swing factor is whether the repaired leadership narrative translates into sustained estimate beats. If not, the current rerating will look like a multiple reset rather than a new growth regime.

Key Decisions for Investors

• Stay long UNH but use strength to trim: keep a core position for 3-6 months, but take partial profits into further upside from current levels; the stock now needs execution, not just policy support, to extend meaningfully.
• Pair long UNH / short HUM over the next 1-2 quarters: UNH has the cleaner balance of policy relief and management credibility, while HUM has more exposed downside if Medicare Advantage economics remain noisy.
• Buy UNH call spreads 2-4 months out rather than outright stock if entering fresh: the move is extended, but the next catalyst window is earnings and guidance, so defined-risk upside is preferable to chasing spot.
• Watch for a re-entry point on any 5-8% pullback tied to utilization headlines: that would likely reset implied expectations without invalidating the broader thesis.
• If policy optimism broadens into the whole sector, consider a sector-neutral long UNH / short broader healthcare ETF hedge to isolate idiosyncratic execution alpha from beta.